Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT14 | O95848 | 1/20 | 0.69 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.67 |
| ▸ | PRKDC | P78527 | 13/20 | 0.67 |
| ▸ | ABL1 | P00519 | 13/20 | 0.67 |
| ▸ | SRC | P12931 | 13/20 | 0.67 |
| ▸ | EGFR | P00533 | 12/20 | 0.67 |
| ▸ | MTOR | P42345 | 11/20 | 0.67 |
| ▸ | HCK | P08631 | 11/20 | 0.67 |
| ▸ | KDR | P35968 | 11/20 | 0.67 |
| ▸ | EPHB4 | P54760 | 10/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30782445 | 1.00 | NUDT14 (0.69) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL13826003 | 0.89 | SRC (0.68) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL16886112 | 0.88 | PIK3CD (0.68) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL13019672 | 0.88 | SRC (0.69) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL21079131 | 0.88 | NUDT14 (0.66) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23917243 | 0.88 | KDM4E (0.69) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL130419 | 0.88 | PIK3CD (0.70) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL409367 | 0.88 | PIK3CD (0.82) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23917506 | 0.86 | NUDT14 (0.64) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB | |
| SCHEMBL13826048 | 0.85 | NUDT14 (0.63) | NUDT14NUDT5PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| WO-2023016296-A1 | HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| CN-110036014-B | Compound with AXL inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2021-09-07 | — | — | CN | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
| WO-2011055215-A2 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010045542-A2 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | NUDT14 1403/4885NUDT5 2424/4885PIK3CD 47/4885 |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NUDT14 2645/4885NUDT5 2259/4885PIK3CD 145/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | NUDT14 1403/4885NUDT5 2424/4885PIK3CD 47/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | NUDT14 1304/4885NUDT5 2607/4885PIK3CD 70/4885 |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | IRAK2, IRAK3, IRAK1 | NUDT14 2508/4885NUDT5 2045/4885PIK3CD 240/4885 |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | NUDT14 1939/4885NUDT5 2913/4885PIK3CD 276/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | NUDT14 2673/4885NUDT5 3615/4885PIK3CD 103/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | NUDT14 1304/4885NUDT5 2607/4885PIK3CD 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.